top of page

Israel: a new technological service for more efficient drug development

Writer's picture: Caroline HaïatCaroline Haïat



PhaseV, a pioneer in software and machine learning (ML) for adaptive clinical trial optimization, operating in Israel announced its partnership with global biometric clinical research organization (CRO) Quanticate on a new technology service that allows biopharmaceutical companies to improve the speed and quality of clinical development programs.


The new partnership leverages Quanticate's flexible solutions for clinical data management, biostatistics and statistical programming, as well as PhaseV's proprietary software and ML platform for adaptive testing, and enables the team of statistical consultants to Quanticate to quickly assess whether a sponsor's trial is a good fit for an adaptive design. After evaluation, the service will include in-depth design, in addition to high-quality execution of the adaptive trial and comprehensive analysis to support effective and efficient drug development.


“There is currently a great need in the pharmaceutical industry to leverage flexible, dynamic and adaptive trial designs based on simulations, machine learning and data accumulation throughout a trial, while continuing to maintain the highest scientific integrity,” said David Underwood, CEO of Quanticate. "The PhaseV platform allows teams to seamlessly evaluate and execute all types of designs. We are excited to enhance our services and drive innovation in drug development through this collaboration."


The designs have the potential to significantly increase efficiency while increasing overall testing quality. The collaboration and joint offering of PhaseV and Quanticate will help sponsors overcome these challenges while enjoying the benefits of a design tailored to their specific needs and objectives.


“Adaptive trials have the potential to increase the throughput of clinical development. However, for this to happen, sponsors must overcome some key challenges, including operational and data implications,” said Dr. Raviv Pryluk, CEO and co-founder of PhaseV. "High-quality implementation and careful integration with data management systems, along with best-in-class service staffed by biostatisticians, regulatory and medical experts, are required. Quanticate has become the trusted provider of numerous biotechnology and device companies as well as global pharmaceutical giants."


Quanticate is one of the world's largest biometric clinical research organizations (CROs), primarily focused on data collection and validation, statistical analysis, and clinical trial writing. As a clinical data expert, with a long history spanning three decades, Quanticate can quickly deliver high-quality teams with flexible solutions.


Caroline Haïat


0 comments

Recent Posts

See All

Kommentare


bottom of page